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D-2-hydroxyglutaric aciduria is a neurometabolic disorder with both a mild and a severe phenotype and with
unknown etiology. Recently, a novel enzyme, D-2-hydroxyglutarate dehydrogenase, which converts D-2-hydroxy-
glutarate into 2-ketoglutarate, and its gene were identified. In the genes of two unrelated patients affected with D-
2-hydroxyglutaric aciduria, we identified disease-causing mutations. One patient was homozygous for a missense
mutation (c.1331TrC; p.Val444Ala). The other patient was compound heterozygous for a missense mutation
(c.440TrG; p.Ile147Ser) and a splice-site mutation (IVS1-23ArG) that resulted in a null allele. Overexpression
studies in HEK-293 cells of proteins containing the missense mutations showed a marked reduction of D-2-hy-
droxyglutarate dehydrogenase activity, proving that mutations in the D-2-hydroxyglutarate dehydrogenase gene
cause D-2-hydroxyglutaric aciduria.
D-2-hydroxyglutaric aciduria (D-2-HGA) is a neuro-
metabolic disorder, first described in 1980 (Chalmers et
al. 1980). To date, 130 patients with D-2-HGA have
been reported. The diagnosis is based on increased levels
of D-2-hydroxyglutarate (D-2-HG) in body fluids, de-
tected by analytic methods that separate and quantify
individually the two isomers of 2-HG. Clinical symp-
toms of patients with D-2-HGA are developmental delay,
epilepsy, hypotonia, and dysmorphic features. In an in-
ternational survey of clinical data, both a mild and a
severe phenotype could be distinguished (van der Knaap
et al. 1999). The severe phenotype is homogeneous and
is characterized by early-infantile-onset epileptic en-
cephalopathy and, often, cardiomyopathy. Magnetic res-
onance imaging (MRI) reveals signs of disturbed cerebral
maturation and white-matter abnormalities. The mild
phenotype has a more variable clinical presentation and
less-consistent MRI findings than the severe phenotype.
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In the 25 years since the recognition of D-2-HGA, little
progress has been made in understanding the biochem-
ical and genetic basis of this disorder. Recently, the iso-
lation and characterization of a dehydrogenase acting
on D-2-HG was described (Achouri et al. 2004). This
mitochondrial enzyme converts D-2-HG to 2-ketoglu-
tarate with a Km value !10 mM, is homologous to flavin
adenine dinucleotide–dependent D-lactate dehydroge-
nase, and most likely transfers its electrons to electron-
transfer flavoprotein. Assays of D-2-hydroxyglutarate
dehydrogenase in rat tissues indicate that this enzyme is
most active in liver and kidney but is also active in heart
and brain (E.V.S., unpublished data). Levels of D-2-HG
in body fluids of healthy human individuals are at the
low micromolar level, suggesting that D-2-hydroxyglu-
tarate dehydrogenase is an important enzyme in the dis-
posal of D-2-HG.
To determine whether mutations in the D-2-hydroxy-
glutarate dehydrogenase gene cause D-2-HGA, we in-
vestigated this gene by genomic and cDNA sequence
analysis in two unrelated patients affected with the se-
vere phenotype of D-2-HGA.
Patient 1 was a white Italian boy born to consan-
guineous healthy parents (first cousins). Clinical assess-
ment revealed mild facial dysmorphia, with a reduced
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Table 1
D-2-Hydroxyglutarate Dehydrogenase Activity in HEK-293
Cells Overexpressing the Wild-Type or Mutated Human
Enzyme
Transfected
D-2-Hydroxyglutarate Dehydrogenase
Activitya
(pM/min/mg protein)
Wild type 2.00  .3
Val444Ala mutant .5  .1
Ile147Ser mutant 0
NOTE.—Transient transfections were performed as described
elsewhere (Achouri et al. 2004). The nucleic acid sequences of
the mutated plasmids were confirmed by sequence analysis. The
enzymatic activity was assayed by use of the radiochemical as-
say in the presence of 2 mM D-2-hydroxyglutarate without
added Co2.
a Activities are expressed as the activity observed after sub-
traction of the value in nontransfected HEK cells (0.16 0.02
pM/min/mg protein). Data are mean  SEM of three or four
transfections.
bitemporal diameter, a prominent forehead, and mi-
crognathia. The patient exhibited psychomotor retar-
dation, experienced episodes of vomiting, and suffered
from tonic, tonic-clonic, and myoclonic seizures that
were not responsive to antiepileptic treatment. He died
at 2 years of age. Quantitative measurements of D-2-
HG showed urine levels at 502 mM/M creatinine (nor-
mal, !18 mM/M creatinine), plasma levels at 26 mM/l
(normal, !1mM/l), and cerebrospinal fluid levels at 6
mM/l (normal, !0.4 mM/l). L-2-HG was within the ref-
erence range, in all samples. Two siblings died with
symptoms similar to those observed in the patient (no
data available), and one sibling is unaffected.
In the D-2-hydroxyglutarate dehydrogenase gene of
patient 1, a homozygous TrC transition (c.1331TrC)
that results in the substitution of alanine for valine at
position 444 (p.Val444Ala) was found in exon 9 (see
fig. 1). The parents were heterozygous for this mutation,
proving homozygosity in their affected child. Valine and
alanine belong to the same group of amino acids with
aliphatic side chains, with a methyl group for alanine
and a three-carbon unit for valine. In a multiple se-
quence alignment of available protein sequences, the
valine 444 is conserved in the mouse D-2-hydroxyglu-
tarate dehydrogenase and in the “actin-interacting pro-
tein 2” (NCBI accession number P46681) of Sacchar-
omyces cerevisiae (Achouri et al. 2004). Overexpression
of the mutant protein in HEK-293 cells showed that this
amino acid change results in marked reduction of D-2-
hydroxyglutarate dehydrogenase activity (table 1).
These observations and the absence of the mutation in
210 control chromosomes indicate that the mutation
is pathogenic.
Patient 2 was a white American girl born to noncon-
sanguineous parents of mixed ethnic ancestry. Her clin-
ical details have been described elsewhere (Gibson et al.
1993). She presented with generalized tonic-clonic sei-
zures, infantile spasms with hypsarrhythmia, hypotonia,
a movement disorder, cortical blindness, and develop-
mental delay. Quantitative measurements of D-2-HG
showed urine levels at 1,747 mM/M creatinine, plasma
levels at 73 mM/l, and cerebrospinal fluid levels at 25
mM/l. L-2-HG was within the reference range, in all
samples.
In the D-2-hydroxyglutarate dehydrogenase gene of
this patient, a heterozygous missense mutation in exon
2 and a heterozygous mutation in intron 1 were found
(see fig. 1). The missense mutation consists of a TrG
transversion at position 440 (c.440TrG), resulting in
the substitution of serine for isoleucine (p.Ile147Ser).
Isoleucine is conserved in the mouse D-2-hydroxygluta-
rate dehydrogenase protein and in the actin-interacting
protein 2 of S. cerevisiae (Achouri et al. 2004). The
conservation of isoleucine, the differences in the chem-
ical properties of serine versus isoleucine, and the ab-
sence of this mutation in 210 control chromosomes
suggest that this substitution is pathogenic. Indeed,
overexpression in HEK-293 cells of the mutant protein
containing p.Ile147Ser proved that the amino acid
change results in marked reduction of D-2-hydroxyglu-
tarate dehydrogenase activity (table 1).
The heterozygous mutation in intron 1, IVS1-23ArG,
was not found in 210 control chromosomes and thus
could represent a pathogenic mutation. RT-PCR was
performed on RNA isolated from cultured fibroblasts of
the patient and showed that only the allele containing
the missense mutation was present, which indicates that
the second allele is a null allele. mRNA was isolated
from fibroblasts that were incubated for 5 h with cyclo-
heximide (0.25 mg/ml), an inhibitor of protein synthe-
sis, which avoids nonsense-mediated decay. RT-PCR
analysis using this mRNA identified the structure of
the second mutant allele. It arises as a result of the cre-
ation of an alternative splice-acceptor site located 19
nt upstream of the wild-type splice-acceptor site, lead-
ing to the insertion of 19 nt into the mature mRNA
(r.295_296ins19), and it involves the IVS1-23ArG site.
This insertion results in a frameshift that causes a pre-
mature stop (p.Cys100fsX9). The combination of a null
allele and a pathogenic missense mutation indicates that,
in this patient, D-2-HGA is caused by a deficiency of D-
2-hydroxyglutarate dehydrogenase.
Our data show, for the first time, that mutations in
the D-2-hydroxyglutarate dehydrogenase gene can cause
D-2-HGA. This result proves that D-2-HGA is an inborn
error of metabolism with autosomal recessive inher-
itance and is consistent with our previous studies in
which we found increased levels of D-2-HG in culture
media of fibroblasts from patients with D-2-HGA (Struys
et al. 2003). The low activities of D-2-hydroxyglutarate
dehydrogenase in fibroblasts, leukocytes, and lympho-
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Figure 1 Schematic presentation of the D-2-hydroxyglutarate dehydrogenase gene, showing exons (numbered blackened boxes) and introns
(see Genbank for genomic DNA [accession number 27465811] and cDNA [accession number 22477763]). The three pathogenic mutations that
were found in two patients affected with D-2-HGA are shown. The IVS1-23ArG mutation creates an alternative splice-acceptor site located
19 nt upstream of the wild-type splice-acceptor site (r.295_296ins19). Figure is drawn to scale.
cytes, however, do not allow accurate measurement by
radiochemical assay (Achouri et al. 2004), which is the
only available method for this enzyme to date. In this
procedure, racemic [2-3H]D/L-2-HG is used as the sub-
strate, requiring the separation of D-2-hydroxyglutarate
dehydrogenase and L-2-hydroxyglutarate dehydroge-
nase (Rzem et al. 2004) prior to the enzyme assay. This
is obligatory, since both D-2-hydroxyglutarate dehydro-
genase and L-2-hydroxyglutarate dehydrogenase act on
[2-3H]D/L-2-HG, yielding titrated water, which makes
the assay nonspecific. Alternatively, if the racemic sub-
strate [2-3H]D/L-2-HG could be separated into enanti-
omeric pure substrates by chromatographic techniques,
then the assay would become specific for the corre-
sponding hydroxyglutarate dehydrogenase. Unfortu-
nately, both the separation of the enzymes from fibro-
blasts, leukocytes, and lymphocytes and the separation
of the racemic substrate are not feasible at this time.
Although the pathophysiologic mechanism by which
D-2-HGA causes neurologic dysfunction remains un-
known, the elucidation of disease-causing mutations in
the D-2-hydroxyglutarate dehydrogenase gene extends
prenatal diagnoses from the established measurement
of D-2-HG in amniotic fluid to DNA analysis during
the first trimester for families with proven pathogenic
mutations.
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